A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
Recruitment status was Recruiting
For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer. For some patients, the removal of a lobe of lung may leave too little lung behind for easy breathing. For some of these patients, it may be possible to perform a smaller-scale surgery ("sub-lobar resection") and place a radioactive implant behind to prevent the cancer from growing back. This study will see how these patients do in terms of controlling their disease treated with a radioactive implant called Cesium-131.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Outcome Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage NSCLC|
- Local Recurrence [ Time Frame: 3 Years ] [ Designated as safety issue: No ]Cancer regrowth in the area where it was surgically removed
- Quality of Life [ Time Frame: 2 years ] [ Designated as safety issue: No ]Using questionnaires, data will be collected related to the sense of well-being experienced by the patient after treatment.
|Study Start Date:||November 2010|
|Estimated Study Completion Date:||May 2014|
|Estimated Primary Completion Date:||May 2014 (Final data collection date for primary outcome measure)|
Sub-lobar resection with Cesium-131
All enrolled patients will undergo sub-lobar resection and brachytherapy implant with Cesium-131 in an effort to study and quantify recurrence/control patterns.
Radiation: Cesium-131 Brachytherapy Seed
85 Gray Dose
Other Name: Sealed Brachytherapy Source CS-1 (IsoRay Medical)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01237171
|United States, New York|
|Weill Cornell Medical College||Recruiting|
|New York, New York, United States, 10021|
|Contact: Bhupesh Parashar, M.D. 212-746-3612 firstname.lastname@example.org|
|Contact: Mei-Ki Chan, M.A. 212-746-9297 email@example.com|
|Principal Investigator: Bhupesh Parashar, M.D.|
|Principal Investigator:||Bhupesh Parashar, M.D.||Weill Medical College of Cornell University|